Skip to main content

Table 4 Mean homocysteine concentration at follow up* according to treatment group and fracture outcomes

From: The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial

 

With fracture mean (standard deviation)

Without fracture mean (standard deviation)

Difference, (95% confidence interval)

P-value (paired t-test)

Homocysteine (micromol/L

    

Placebo (n = 584)

15.7 (5.9) (n = 23)

14.2 (6.1) (n = 561)

−1.52 (−4.08,1.04)

0.2447

B-Vitamins (n =580)

11.7 (9.6) (n = 18)

10.5 (4.6) (n = 562)

−1.17 (−3.46,1.11)

0.3118

  1. * The difference between baseline and follow-up Homocysteine levels were also compared between patients with and without facture. The differences are not significant, either (data not shown).
  2. Note: Only a small subset of patients (14.3%) had homocysteine levels measured at final follow up.